45x Ab-conjugated beads (S5P5 - human IL-5 Ab-bead). PN: A111176TA. One vial containing 35 µL of anti-human IL-5 conjugated to AimPlex Bead S5P5.
25x Biotin-detection Ab (human IL-5 Biotin-dAb). PN: A111176TB. One vial containing 35 µL of biotinylated anti-human IL-5.
Lyophilized Standard Mix-Human Group 2 Panel A, 10-Plex. PN: HG2009A. One vial containing lyophilized recombinant human G-CSF, GM-CSF, IFNα2, IL-1α, IL-3, IL-5, IL-7, IL-11, IL-12p40, and IL-13. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
STORAGE: 2-8 C in the dark.
IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
APPLICATION: Optimal antibody pair and antigen standard for assaying human IL-5. Can be multiplexed with other analytes in Human Group 2. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 2 pg/mL
LLOQ: < 5 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 2 Negligible
Sample volume: 15 µL/test
Interleukin 5 (Accession P05113) or Eosinophil Differentiation Factor (EDF) is produced by both hematopoietic and non-hematopoietic cells such as T cells and granulocytes. IL-5, along with IL-3, and GM-CSF are mediators for eosinophil differentiation, though IL-5 has an eosinophil specificity and plays a role in their maturation. Overexpression of IL-5 in vivo increases amounts of B cells (mostly in mice), eosinophils (in humans), and antibodies significantly. Targeting IL-5 expression may have implications for such conditions as food allergies, asthma, inflammatory bowel diseases, and drug hypersensitivity.
Kiyoshi T, Nakajima H. IL-5 and Eosinophila.
Kouro T, Takatsu K. IL-5-and eosinophil-mediated inflammation: from discovery to therapy. Int. Immunol. 2009. Dec 21(12): 1303-9. Doi:10.1093/intimm/dxp102. PMID: 19819937.
Sanderson CJ. Eosinophil Differentiation Factor (Interleukin-5). Immunol Ser. 1990; 49:231-56. PMID: 2090253.
Takatsu K. Interleukin-5 and IL-5 Receptor in Health and Diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87(8): 463-85. Doi: 10.2183/pjab.87.463. PMID: 21986312.
Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K. Allergic diseases: From bench to clinic – Contribution of the discovery of interleukin-5. Cytokine. 2017 Oct; 98:59-70. Doi:10.1016/j.cyto.2016.11.011.